IQVIA, Inc. announced the partnership with Argenx SR by signing a multi-year contract. It covers the creation of additional indications for VYVGARTTM, an FDA-approved neonatal Fc receptor blocker for the treatment of generalized myasthenia gravis in individuals over the age of 18.
ICON plc signed a concluding agreement to completely acquire PRA Health Sciences, Inc. The buy-out has been finalized in stock and cash transaction of USD 12 Billion. With this acquisition, the two companies aim to execute high-quality and effectively clinical trials from Phase 1 through post-approval studies.
Author Credits: Radhika Gupta, Shivam Bhutani